ACADIA Pharmaceuticals Inc.

ACAD Healthcare Biotechnology

ACADIA Pharmaceuticals Inc.’s revenue for fiscal 2025 (year ended December 2025) was $1.1 billion, up 11.9% from fiscal 2024. In the quarter to June 2026, revenue grew 16.4%, EPS grew 12.5% and free cash flow grew 50.3%, each against the same quarter a year earlier. Revenue growth for ten consecutive years.

19.12 0.59 −2.99%
Market cap
$3.4B
P/E
8.5×
Fwd P/E
55.6×
Dividend yield
—
F-score
6/9
Altman Z
7.90
Beneish M
−0.89
Dividend safety
n/a
Dec '16 Dec '17 Dec '18 Dec '19 Dec '20 Dec '21 Dec '22 Dec '23 Dec '24 Dec '25
P/E ratio
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 13.49 11.51
Piotroski F-Score
3 5 6 6 4 4 4 5 4 6
Altman Z-Score
44.08 39.37 16.22 42.35 29.17 10.59 3.00 6.38 3.41 7.90
P/S ratio
192.33 29.87 9.15 18.57 19.04 7.74 5.10 6.96 3.17 4.20
P/FCF ratio
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 25.96 0.00
Altman Z″-Score (non-manufacturers)
9.95 (2.80) 1.95 5.27 (1.37) (3.21) (9.19) (6.64) (0.05) 3.79
Beneish M-Score
250.24 1.51 (2.50) (2.44) (2.69) (2.32) (3.42) (2.45) (2.27) (0.89)
P/Operating CF
(54.47) (124.79) (52.38) (211.98) (305.98) (162.02) (110.62) 59.21 75.31 (92.28)
P/B ratio
6.43 11.13 4.27 9.01 13.41 6.93 6.59 11.71 4.15 3.66
Price to Tangible BV
6.52 11.31 4.31 9.04 13.44 6.93 6.60 13.80 4.96 4.02
EV/Sales
161.81 27.14 7.03 16.52 17.61 6.66 4.30 6.36 2.39 3.43
EV/EBITDA
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 9.63 33.08
EV/Operating CF
(13.46) (15.57) (9.40) (37.05) (57.13) (25.67) (19.49) 276.42 14.49 33.48
EV/FCF
(13.36) (15.51) (9.28) (36.78) (54.11) (25.44) (19.30) (197.73) 19.51 (39.55)
Quick Ratio
12.59 7.34 8.42 9.83 6.44 6.10 3.82 2.13 2.18 3.49
Current Ratio
12.87 7.62 8.83 10.16 6.77 6.43 4.04 2.42 2.38 3.83
Net Debt/EBITDA
1.95 1.18 1.93 2.82 2.24 3.16 1.86 5.82 (3.18) (7.37)
Debt/Assets
0.03% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Debt/Equity
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Asset Turnover
0.04 0.26 0.48 0.51 0.56 0.65 0.80 1.09 0.99 0.78
Operating CF/Net income
0.77 0.75 0.68 0.64 0.48 0.75 0.53 (0.27) 0.70 0.28
Capex/Depreciation
(4.96) (0.34) (0.87) 1.33 (1.72) (0.20) 0.00 20.22 (0.08) (0.74)
ROE
(75.58%) (67.80%) (60.22%) (39.93%) (42.47%) (28.75%) (45.89%) (14.73%) 38.89% 39.89%
ROA
(69.32%) (61.21%) (53.03%) (35.55%) (35.97%) (22.64%) (33.54%) (9.17%) 23.39% 28.42%
ROIC
0.00% 0.00% (2,782.02%) (9,032.28%) 0.00% (527.66%) 0.00% 0.00% 0.00% 16.07%
Return on Tangible Assets
(53.38%) (88.47%) (52.19%) (34.16%) (45.36%) (31.69%) (55.62%) (16.72%) 41.35% 49.34%
Average Days of Receivables
150.37 53.86 45.32 40.77 41.55 49.26 44.51 51.43 39.90 50.49
Research and Development Expense of Revenue
572.87% 119.45% 83.63% 70.89% 72.24% 49.45% 69.91% 48.40% 31.66% 30.69%
Selling, General and Administrative Expense of Revenue
1,075.85% 204.21% 118.74% 96.04% 87.98% 81.80% 71.36% 55.97% 50.99% 51.23%
Intangible Assets out of Total Assets
0.01 0.01 0.01 0.00 0.00 0.00 0.00 0.09 0.10 0.07
Share Based Compensation of Revenue
318.88% 60.47% 36.44% 24.26% 19.11% 13.14% 13.19% 9.14% 7.00% 4.87%
Graham Net Nets
0.15 0.09 0.23 0.11 0.07 0.12 0.12 0.06 0.16 0.16
Graham Number
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 11.63 19.51
Earnings Yield
(8.13%) (7.72%) (12.06%) (3.74%) (3.37%) (4.50%) (8.21%) (1.24%) 7.41% 8.69%
Free Cash Flow Yield
(6.30%) (5.86%) (8.28%) (2.42%) (1.71%) (3.38%) (4.36%) (0.46%) 3.85% (2.07%)
Revenue per Share
0.15 1.02 1.77 2.30 2.81 3.02 3.20 4.43 5.78 6.36
Operating CF per Share
(1.80) (1.78) (1.32) (1.03) (0.87) (0.78) (0.71) 0.10 0.95 0.65
Capex per Share
(0.08) (0.01) (0.02) (0.01) (0.05) (0.01) 0.00 (0.24) 0.00 (0.03)
Free Cash Flow per Share
(1.88) (1.78) (1.34) (1.03) (0.91) (0.79) (0.71) (0.14) 0.95 0.62
Cash per Share
4.57 2.78 3.74 4.74 4.02 3.24 2.58 2.68 4.56 4.87
Shareholders Equity per Share
4.47 2.73 3.78 4.75 3.99 3.37 2.48 2.64 4.42 7.29
Interest Debt per Share
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Book value per Share
4.47 2.73 3.78 4.75 3.99 3.37 2.48 2.64 4.42 7.29
Free Cash Flow
(217.91) (218.57) (169.57) (152.26) (143.75) (126.78) (114.03) (23.35) 157.20 105.15
Working Capital
505.31 324.45 466.54 685.42 611.65 521.76 382.31 361.87 543.45 785.00
Capital Expenditures
(9.51) (0.81) (2.10) (1.13) (7.59) (1.12) — (40.05) (0.52) (4.69)
Net Current Asset Value
505.16 324.26 464.98 676.20 562.01 458.60 320.54 298.92 483.36 725.31
EV/EBIT
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 9.90 35.08
Capex to Sales
0.55 0.01 0.01 0.00 0.02 0.00 0.00 0.06 0.00 0.00
Price to Operating Income
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 13.18 42.90
Other line items
Depreciation/Fixed assets
0.62 0.91 0.73 (0.27) 0.48 0.71 (0.12) (0.43) 1.56 0.84
Cash ROIC
(20.80%) (32.30%) (17.80%) (10.90%) (11.42%) (11.94%) (13.95%) (2.68%) 10.56% 5.14%
Accounts Receivable Turnover
3.95 9.77 9.68 10.33 10.02 8.37 8.06 8.78 9.25 8.47
Accounts Payable Turnover
1.10 1.43 2.07 2.18 1.30 2.49 1.04 2.75 4.85 6.57
Inventory Turnover
0.65 1.93 2.66 2.18 1.27 2.18 1.40 1.96 2.83 3.14
Average Days of Payables
464.35 353.30 93.40 232.37 303.59 131.12 457.63 153.78 72.21 44.72
Days of Inventory on Hand
495.57 211.03 120.03 204.03 346.09 150.28 238.26 313.99 97.89 142.19
Average Receivables
4.39 12.79 23.11 32.83 44.08 57.81 64.21 82.72 103.52 126.46
Average Payables
2.79 6.35 5.98 5.19 7.86 7.68 9.81 15.14 16.87 13.55
Average Inventory
4.71 4.71 4.66 5.21 8.01 8.78 7.26 21.23 28.88 28.31
Average Assets
391.52 472.83 462.35 661.69 782.90 741.37 643.97 668.38 968.36 1,375.98
Average Common Equity
359.09 426.85 407.18 589.11 663.07 583.95 470.65 416.08 582.27 980.09

Fold the line items

Columns are period end dates